Screener
Allogene Therapeutics ALLO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's debt-to-equity?
- Allogene Therapeutics (ALLO) reported debt-to-equity of 0.3× in Q1 2026.
- How has Allogene Therapeutics's debt-to-equity changed year-over-year?
- Allogene Therapeutics's debt-to-equity increased by 26.0% year-over-year, from 0.2× to 0.3×.
- What is the long-term trend for Allogene Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Allogene Therapeutics's debt-to-equity has grown at a 39.9% compound annual growth rate (CAGR), from 0.1× to 0.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Allogene Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude